Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.72 USD | +5.68% | -2.62% | -62.08% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-62.08% | 997M | C | ||
+9.15% | 221B | B | ||
+18.60% | 142B | B- | ||
+18.70% | 101B | A- | ||
+7.87% | 68.07B | A- | ||
+24.79% | 57.27B | B+ | ||
-2.49% | 47.42B | B+ | ||
+6.00% | 43.19B | A | ||
+16.80% | 41.12B | - | ||
+14.13% | 28.84B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Pacific Biosciences of California, Inc. - Nasdaq
- Ratings Pacific Biosciences of California, Inc.